

**26<sup>th</sup> May 2017**

The Manager - Listing  
**BSE Limited**  
Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai 400001

**Subject: Outcome of Board Meeting****Scrip Code: 531207**


Dear Sir/Madam,

This is to inform you that the Board of Directors of the company, in their meeting held today, i.e. Friday, 26<sup>th</sup> May, 2017 (commenced at 11.00 A.M. and concluded at 3.30 P.M.), have considered and approved, inter-alia, the following business:

1. Consideration and approval of the Audited Financial Results as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the quarter and year ended 31<sup>st</sup> March 2017. **(Copy Enclosed)**
2. The Board considered and took on record, the Auditors' Report on Annual Financial Results for the Quarter and year ended 31<sup>st</sup> March 2017 as placed by the Statutory Auditor of the Company. **(Copy Enclosed)**
3. Declaration of unmodified opinion on Auditor's Report on annual financial results for the quarter and year ended 31<sup>st</sup> March 2017. **(Copy Enclosed)**
4. The Board took note of Statement of Investor Complaints/Grievances given Under Regulation 13(3) of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 for the quarter ended 31<sup>st</sup> March 2017.
5. The Board had appointed M/s Jain P & Associates, Practicing Company Secretaries, as Secretarial Auditor for the financial year 2016-17.

Kindly take the above information on your records.

Sincerely,

**For Raymed Labs Limited****Ajai Goyal**  
**Whole Time Director****DIN: 02636418****R/o: 103 Emperor One, Supertech Emerald Court**  
**Sector 93A, Noida 201304**

## Raymed Labs Limited

Regd. Office: 703 Aster 7, Supertech Emerald Court, Sector 93A, Noida - 201304, Uttar Pradesh, CIN: L24111UP1992PLC014240  
E-Mail: raymedlabs@rediffmail.com, Website: www.raymedlab.com, Tel: 0120-2426900, 9412700300

### Annexure I to Regulation 33

#### Statement of Standalone Audited Financial Results for the Quarter & Year Ended on March 31, 2017

		Quarter Ended			Year Ended		
	Particulars	3 Months Ended 31-03-2017	Preceding 3 Months Ended 31-12-2016	Corresponding 3 Months in the Previous Year Ended 31-03-2016	Year to Date Figures for Current Period Ended 31-03-2017	Year to Date Figures for the Previous Year Ended 31-03-2016	Previous Year Ended 31-03-2016
		Audited	Unaudited	Audited	Audited	Audited	Audited
I	Revenue from Operations						
	(a) Net Sales / Income from Operations (Net of excise duty)	-	-	-	-	-	-
	(b) Other Operating Income	-	-	-	-	-	-
II	Other Income	0.30	0.30	0.30	1.20	1.92	1.92
III	Total Revenue (I+II)	0.30	0.30	0.30	1.20	1.92	1.92
IV	Expenses						
	(a) Cost of materials consumed	-	-	-	-	-	-
	(b) Purchase of stock-in-trade	-	-	-	-	-	-
	(c) Changes in inventories of finished goods, Work-in-progress and stock-in-trade	-	-	-	-	-	-
	(d) Employee Benefits Expenses	0.23	0.19	0.23	1.22	0.90	0.90
	(e) Finance Costs	-	-	-	-	-	-
	(f) Depreciation and amortisation expense	0.05	0.22	0.89	0.71	0.89	0.89
	(g) Other expenses	0.38	0.62	0.26	1.97	1.63	1.63
	Total Expenses	0.66	1.02	1.38	3.91	3.42	3.42
V	Profit/(Loss) before exceptional and extraordinary items and tax (III-IV)	(0.36)	(0.72)	(1.08)	(2.71)	(1.50)	(1.50)
VI	Exceptional Items	-	-	2.25	2.29	2.25	2.25
VII	Profit/(Loss) before extraordinary items and tax (V-VI)	(0.36)	(0.72)	(3.32)	(5.00)	(3.75)	(3.75)
VIII	Extraordinary items	-	-	-	-	-	-
IX	Profit/(Loss) before tax (VII-VIII)	(0.36)	(0.72)	(3.32)	(5.00)	(3.75)	(3.75)
X	Tax Expense	-	-	-	-	-	-
	(1) Current tax	-	-	-	-	-	-
	(2) Deferred tax	-	-	-	-	-	-
XI	Net Profit/(Loss) for the period from continuing operations (IX-X)	(0.36)	(0.72)	(3.32)	(5.00)	(3.75)	(3.75)
XII	Profit/(Loss) from discontinuing operations before tax	-	-	-	-	-	-
XIII	Tax expense of discontinuing operations	-	-	-	-	-	-
XIV	Profit/(Loss) from Discontinuing operations (after tax) (XII-XIII)	-	-	-	-	-	-
XV	Profit/(Loss) for period before Minority interest	-	-	-	-	-	-
	Share of profit/Loss of Associates	-	-	-	-	-	-
	Profit/(Loss) of Minority interest	-	-	-	-	-	-
XVI	Profit/(Loss) for the period (XI+XIV)	(0.36)	(0.72)	(3.32)	(5.00)	(3.75)	(3.75)
XVII	Paid-up share capital (Face Value of the share shall be indicated)	427.35	427.35	427.35	427.35	427.35	427.35
XVIII	Reserve excluding revaluation reserve as per balance sheet of previous accounting year	-	-	-	-	-	-
XIX	Earning Per Equity Share						
	(a) Basic	-0.008	-0.017	-0.078	-0.117	-0.088	-0.088
	(b) Diluted	-0.008	-0.017	-0.078	-0.117	-0.088	-0.088

**Notes:**

- 1 The above results have been reviewed by Audit Committee and taken on record by the Board of Directors at its Meeting held on 26.05.2017. The Statutory Auditors have audited the above results.
- 2 Segment reporting as defined in Accounting Standard (AS-17) is not applicable since the entire operation of the company relates to only one segment.
- 3 In terms of Regulation 13(3) of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, there were no investor complaint pending at the beginning of the quarter or lying unresolved at 31.03.2017.
- 4 The figures have been re-grouped/re-arranged wherever considered necessary.

For Raymed Labs Limited

**For RAYMED LABS LTD**

Ajai Goyal

Whole Time Director

DIN: 02636418

Add.: 103 Emperor 1, Supertech Emerald Court, Sector 93A  
Noida - 201304, Uttar Pradesh

Place: NOIDA

Date: 26-05-2017

**Director**

## Raymed Labs Limited

Regd. Office: 703 Aster 7, Supertech Emerald Court, Sector 93A, Noida - 201304, Uttar Pradesh

CIN: L24111UP1992PLC014240

E-Mail: raymedlabs@rediffmail.com, Website: www.raymedlab.com, Tel: 0120-2426900, 9412700300

### Statement of Assets and Liabilities

Rs. in Lacs

Particulars		As at year end	As at year end
		31-03-2017	31-03-2016
		Audited	Audited
<b>A</b>	<b>EQUITY AND LIABILITIES</b>		
1	Shareholders' Funds		
	(a) Share Capital	427.35	427.35
	(b) Reserves and Surplus	-609.17	-604.17
	(c) Money Received Against Share Warrants	-	-
	Sub-total - Shareholders' Funds	-181.82	-176.82
2	Share Application Money Pending Allotment		
3	Deferred Government Grant		
4	Minority Interest		
5	Non-Current Liabilities		
	(a) Long-Term Borrowings		
	(b) Deferred Tax Liabilities (net)		
	(c) Foreign currency monetary item translation difference liability account		
	(d) Other Long-Term Liabilities		
	(e) Long-Term Provisions		
	Sub-total - Non-Current Liabilities		
5	Current Liabilities		
	(a) Short-Term Borrowings	202.90	198.60
	(b) Trade Payables	-	-
	(i) Total outstanding dues of micro enterprises and small enterprises	-	-
	(ii) Total outstanding dues of creditors other than micro enterprises and small enterprises	-	-
	(c) Other Current Liabilities	6.58	6.15
	(d) Short-Term Provisions	-	-
	Sub-total - Current Liabilities	209.48	204.75
	<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>27.66</b>	<b>27.93</b>
<b>B</b>	<b>ASSETS</b>		
1	Non-Current Assets		
	(a) Fixed Assets		
	Tangible assets	18.54	19.25
	Producing items	0.05	0.06
	Intangible assets	-	-
	Preproducing items	-	-
	Tangible assets capital work-in-progress	-	-
	Intangible assets under development or work-in-progress	-	-
	(b) Non-current Investments	-	-
	(c) Deferred Tax Assets (net)	-	-
	(d) Long-term Loans and Advances	-	-
	(e) Other Non-current Assets	-	-
	Sub-total - Non-Current Assets	18.59	19.31
2	Current Assets		
	(a) Current Investments	-	-
	(b) Inventories	-	-
	(c) Trade Receivables	2.49	2.49
	(d) Cash and Cash Equivalents	0.03	0.03
	(e) Short-term Loans and Advances	6.10	6.10
	(f) Other Current Assets	0.45	-
	Sub-total - Current Assets	9.07	8.62
	<b>TOTAL - ASSETS</b>	<b>27.66</b>	<b>27.93</b>


FOR RAYMED LABS LTD

Ajai Goyal

Ajai Goyal  
Whole Time Director  
DIN: 02636418

Director

Add.: 103 Emperor 1, Supertech Emerald Court, Sector 93A  
Noida - 201304, Uttar Pradesh  
Place: NOIDA  
Date: 26-05-2017



# A. KAY. MEHRA & CO.

C H A R T E R E D   A C C O U N T A N T S

114 ( BASEMENT ), MALL ROAD,  
KINGSWAY CAMP, DELHI-110009  
NEAR GTB NAGAR METRO STATION,  
Ph. No. : 011- 32965997, 9891295255  
E- Mail : akmca1969@gmail.com  
Website : www.akmca.in

## Auditor's Report on Standalone Quarterly Financial Results and Year to Date Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015

To the Board of Directors  
RAYMED LABS LIMITED

We have audited the quarterly financial results of **RAYMED LABS LIMITED** for the quarter ended March 31, 2017 and the year to date results for the period April 1, 2016 to March 31, 2017 attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI(Listing Obligations and Disclosure Requirements), Regulations 2015. These quarterly financial results as well as the year to date financial results have been prepared on the basis of the financial statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these financial results based on our audit of such financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standards for Interim Financial Reporting (AS 25 / Ind AS 34) prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

In our opinion and to the best of our information and according to the explanations given to us these quarterly and year to date financial results:

- i) has been presented in accordance with the requirements of Regulation 33 of the SEBI(Listing Obligations and Disclosure Requirements), Regulations 2015 in this regard; and
- ii) give a true and fair view of the net loss and other financial information for the quarter ended March 31, 2017 as well as the year to date results for the period from April 1, 2016 to March 31, 2017.

Place : NEW DELHI  
Dated : 26.05.2017

For **A. KAY. MEHRA & CO.**  
Chartered Accountants  
(Registration No. 050004C)



**(DEEPAK SUNEJA)**  
PARTNER

Membership No. 501957



# *Raymed Labs Ltd.*

*Manufacturers of Allopathic Medicines*

CIN: L24111UP1992PLC014240

REGISTERED OFFICE,

703, ASTER 7, SUPERTech EMERALD COURT, SECTOR-93A, NOIDA-201304 (U.P.)

e-mail : raymedlabs@rediffmail.com website : www.raymedlab.com

Tel. 0120-2426900, 9412700300

26<sup>th</sup> May 2017

The Head - Listing Compliance  
**BSE Limited**  
Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai 400001

**Subject: Declaration on Audit Report for the year ended 31<sup>st</sup> March 2017**

**Scrip Code: 531207**

Dear Sir/Madam,

We hereby declare, on behalf of **Raymed Labs Limited**, that Audit report in respect to Annual Audited Financial Results for the period ended 31<sup>st</sup> March 2017 submitted by A Kay Mehra Co., Statutory Auditor of the Company, is with unmodified opinion of the Statutory Auditor.

Sincerely,

For **Raymed Labs Limited**

*Ajai Goyal*

**Director**

**Ajai Goyal**

**Whole Time Director**

**DIN: 02636418**

**R/o: 103 Emperor One, Supertech Emerald Court  
Sector 93A, Noida 201304**

*Life is Precious .....and Raymed cares*